Custom service

Custom Bridged Nucleic Acid Synthesis

Synthesize bna/dna and bna/rna chimeric oligonucleotides with peptide-adjacent applications

Turnaround: 4–6 weeksTypical scale: 0.1 mg – 10 g per sequenceChemistry options: BNA monomer incorporation at defined positions; chimera design with DNA/RNA gaps; HPLC/MS oligonucleotide QC

The service is built around BNA monomer incorporation at defined positions. Depending on the molecule we may move to chimera design with DNA/RNA gaps or HPLC/MS oligonucleotide QC to improve stability, loading or yield, and every batch is released with BNA chimera with MS and Tm data.

Because Custom Bridged Nucleic Acid Synthesis projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.

High-affinity antisense probes

SNV-discrimination diagnostic oligos

GMP BNA drug substance

Sequences where a recombinant expression route is objectively cheaper and faster

Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.

Service Highlights

  • BNA monomer incorporation at defined positions as the default route, with chimera design with DNA/RNA gaps held as a proven fallback
  • HPLC/MS oligonucleotide QC worked into the design where the application requires it
  • Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
  • Analytical confirmation of every intermediate before the final release
  • Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
  • BNA chimera with MS and Tm data delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Sequence analysis

    Custom Bridged Nucleic Acid Synthesis is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.

  2. Route selection

    Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.

  3. Assembly

    The chain is built with BNA monomer incorporation at defined positions applied where the sequence demands it, with double-coupling at hazard sites.

  4. Cleavage & crude QC

    Crude material is characterized so purification targets are set on data, not hope.

  5. Purification

    RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.

  6. Release

    BNA chimera with MS and Tm data is documented with the full analytical package and released.

Specifications & timeline

Turnaround
4–6 weeks
Typical scale
0.1 mg – 10 g per sequence
Chemistry options
BNA monomer incorporation at defined positions; chimera design with DNA/RNA gaps; HPLC/MS oligonucleotide QC
Deliverable
BNA chimera with MS and Tm data
QC package
HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
Shipping
Ambient with desiccant; blue ice for modified or sensitive peptides

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.